Onco Actu du 24 juin 2016

	5.10 Traitements - Essais
They’re going to CRISPR people. What could possibly go wrong? [STAT] Four potential snafus: 1. CRISPR edits DNA it isn’t supposed to 2. CRISPR hits its targets, but then genetic hell breaks loose 3. The Energizer Bunny problem 4. Dollars triumph over data
	5.12 Immunothérapies
The Immuno-oncology Traffic Jam [In the Pipeline] This isn’t all that new a phenomenon in the oncology field, when you think about the number of people who’ve gone after, say, VEGF. You do get the impression, though, that there are going to be a lot of tough calls made with not enough data.
	5.2.2 Pharma - Fusions & Acquisitions
Sanofi Said to Consider Adding Future Payments to Medivation Bid [Bloomberg] Sanofi, the French drugmaker, is considering improving its $9.3 billion takeover offer for Medivation Inc. by committing to making future payments if the U.S. biotech company meets certain targets, according to people familiar with the matter.
	5.2.3 Pharma - économie
Uncertainty for biotech as U.K. exits EU, Prime Minister to resign [FierceBiotech] A weak pound is of course good for exporters and therefore Big Pharma, but this is not the case for most U.K. biotech cos, which typically have little/nothing to export, and rely on continual funding from VCs and others to fund research efforts. The big issue for biotech is how its backers now and in the future will deal with the increased risk prompted by a looming Brexit and months of uncertainty.
	5.3 Traitements - FDA, EMA,...
EMA-ESMO workshop single-arm trials in cancer drug evaluation [EMA] 30th June 2016.
	5.3.4 Traitements - AMM (FDA, EMA)
New cell-based therapy to support stem cell transplantation in patients with high-risk blood cancer [EMA] The common name of Zalmoxis is allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2).
	5.4 Traitements - Economie
Why American Consumers Are Of Two Minds When It Comes To Drug Companies [Forbes] We can reward drug companies based on the clinical efficacy of their drugs if they prefer, or on the cost of development. But they should be required to choose one or the other. They can’t have it both ways.
	6. Lutte contre les cancers
Moonshot Panel Moving Toward Final Report [National Cancer Institute] This past week, the Blue Ribbon Panel gathered in person to discuss approximately 20 preliminary recommendations and cross-cutting themes that have emerged from the working groups’ deliberations.
Lung cancer surgery left her ‘leaking’ and near death. Belly fat saved her life [STAT] So few rigorous scientific studies have been done that “exactly what stem cells do” when put into a patient like Leogrande “has never been determined,” said Dr. David Scadden, codirector of the Harvard Stem Cell Institute.
	6.1 Observation
How the mafia is causing cancer [Mosaic] When doctors in rural Italy began to see a surge in cancer cases, they were baffled. Then they made the link with industrial waste being dumped by local crime syndicates. Ian Birrell learns about the tragic consequences.
	6.10 Politiques
A bill would would speed cheaper versions of pricey biologics to market [STAT] In the latest bid to lower drug costs, a congressional lawmaker has introduced a bill to shorten the exclusive amount of time that companies would have to market expensive biologic medicines from 12 years to seven years.
The ‘Anti-Business’ President Who's Been Good for Business [Bloomberg] What industries would you think about going into? Well, you know, it’s hard to say. ... the conversations I have with Silicon Valley and with venture capital pull together my interests in science and organization in a way I find really satisfying. You know, you think about something like precision medicine...
	6.11 Patients
The bond between cancer survivors is strong. That's why it's so hard when we lose each other [The Guardian] I feel trapped in some pink hamster-wheel cancer hell greased with heartbreak. And there’s no exit.
	6.6 Publications
Libraries May Have Gotten the Privacy Thing All Wrong [The Scholarly Kitchen] A bypass strategy moves the relationship to the end-user, leaving the library with little or no role. What LinkedIn will provide to Microsoft is a trove of end-user information (Google “data is the new oil” ). By analogy, imagine what consumer markets would look like if Apple were to merge with Facebook. But who has that information in the academy?
	6.7 DMP, Big Data & applis
Pharma, Data Veteran Stephen Friend Bites At Apple's Health Offer [Xconomy] Friend’s move to Apple is not out of the blue. Under Friend, Sage has been a major contributor to Apple’s ResearchKit initiative, which allows iPhone users to share personal health data with medical researchers.